386 related articles for article (PubMed ID: 11401111)
1. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group.
Richards AM; Doughty R; Nicholls MG; MacMahon S; Sharpe N; Murphy J; Espiner EA; Frampton C; Yandle TG;
J Am Coll Cardiol; 2001 Jun; 37(7):1781-7. PubMed ID: 11401111
[TBL] [Abstract][Full Text] [Related]
2. Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group.
Richards AM; Doughty R; Nicholls MG; Macmahon S; Ikram H; Sharpe N; Espiner EA; Frampton C; Yandle TG
Circulation; 1999 Feb; 99(6):786-92. PubMed ID: 9989964
[TBL] [Abstract][Full Text] [Related]
3. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction.
Richards AM; Nicholls MG; Yandle TG; Frampton C; Espiner EA; Turner JG; Buttimore RC; Lainchbury JG; Elliott JM; Ikram H; Crozier IG; Smyth DW
Circulation; 1998 May; 97(19):1921-9. PubMed ID: 9609085
[TBL] [Abstract][Full Text] [Related]
4. Effect of Carvedilol on Serum Heart-type Fatty Acid-binding Protein, Brain Natriuretic Peptide, and Cardiac Function in Patients With Chronic Heart Failure.
Sun YP; Wei CP; Ma SC; Zhang YF; Qiao LY; Li DH; Shan RB
J Cardiovasc Pharmacol; 2015 May; 65(5):480-4. PubMed ID: 25945865
[TBL] [Abstract][Full Text] [Related]
5. N-terminal prohormone brain natriuretic peptide plasma levels in heart failure are affected both directly and indirectly by carvedilol.
Kallistratos MS; Dritsas A; Laoutaris ID; Cokkinos DV
Angiology; 2008; 59(3):323-8. PubMed ID: 18388105
[TBL] [Abstract][Full Text] [Related]
6. Concentration of BNP, endothelin 1, pro-inflammatory cytokines (TNF-alpha, IL-6) and exercise capacity in patients with heart failure treated with carvedilol.
Nessler J; Nessler B; Kitliński M; Gackowski A; Piwowarska W; Stepniewski M
Kardiol Pol; 2008 Feb; 66(2):144-51; discussion 152-3. PubMed ID: 18344152
[TBL] [Abstract][Full Text] [Related]
7. Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a beta-blocker: results from the Carvedilol Or Metoprolol European Trial (COMET) trial.
Olsson LG; Swedberg K; Cleland JG; Spark PA; Komajda M; Metra M; Torp-Pedersen C; Remme WJ; Scherhag A; Poole-Wilson P;
Eur J Heart Fail; 2007 Aug; 9(8):795-801. PubMed ID: 17693380
[TBL] [Abstract][Full Text] [Related]
8. Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure.
Sliwa K; Norton GR; Kone N; Candy G; Kachope J; Woodiwiss AJ; Libhaber C; Sareli P; Essop R
J Am Coll Cardiol; 2004 Nov; 44(9):1825-30. PubMed ID: 15519014
[TBL] [Abstract][Full Text] [Related]
9. Effects of carvedilol on plasma B-type natriuretic peptide concentration and symptoms in patients with heart failure and preserved ejection fraction.
Takeda Y; Fukutomi T; Suzuki S; Yamamoto K; Ogata M; Kondo H; Sugiura M; Shigeyama J; Itoh M
Am J Cardiol; 2004 Aug; 94(4):448-53. PubMed ID: 15325927
[TBL] [Abstract][Full Text] [Related]
10. Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial.
Hartmann F; Packer M; Coats AJ; Fowler MB; Krum H; Mohacsi P; Rouleau JL; Tendera M; Castaigne A; Anker SD; Amann-Zalan I; Hoersch S; Katus HA
Circulation; 2004 Sep; 110(13):1780-6. PubMed ID: 15381643
[TBL] [Abstract][Full Text] [Related]
11. Myocardial contractile reserve under low doses of dobutamine and improvement of left ventricular ejection fraction with treatment by carvedilol.
Jourdain P; Funck F; Fulla Y; Hagege A; Bellorini M; Guillard N; Loiret J; Thebault B; Desnos M
Eur J Heart Fail; 2002 Jun; 4(3):269-76. PubMed ID: 12034151
[TBL] [Abstract][Full Text] [Related]
12. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction.
Stanek B; Frey B; Hülsmann M; Berger R; Sturm B; Strametz-Juranek J; Bergler-Klein J; Moser P; Bojic A; Hartter E; Pacher R
J Am Coll Cardiol; 2001 Aug; 38(2):436-42. PubMed ID: 11499735
[TBL] [Abstract][Full Text] [Related]
13. Effect of beta-blockade and ACE inhibition on B-type natriuretic peptides in stable patients with systolic heart failure.
Rosenberg J; Gustafsson F; Remme WJ; Riegger GA; Hildebrandt PR
Cardiovasc Drugs Ther; 2008 Aug; 22(4):305-11. PubMed ID: 18309461
[TBL] [Abstract][Full Text] [Related]
14. Effects of nebivolol versus carvedilol on left ventricular function in patients with chronic heart failure and reduced left ventricular systolic function.
Lombardo RM; Reina C; Abrignani MG; Rizzo PA; Braschi A; De Castro S
Am J Cardiovasc Drugs; 2006; 6(4):259-63. PubMed ID: 16913827
[TBL] [Abstract][Full Text] [Related]
15. The effect of carvedilol on B-type natriuretic peptide and cardiac function in patients with heart failure and persistent atrial fibrillation.
Khand AU; Chew PG; Douglas H; Jones J; Jan A; Cleland JG
Cardiology; 2015; 130(3):153-8. PubMed ID: 25660493
[TBL] [Abstract][Full Text] [Related]
16. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide.
Omland T; Aakvaag A; Bonarjee VV; Caidahl K; Lie RT; Nilsen DW; Sundsfjord JA; Dickstein K
Circulation; 1996 Jun; 93(11):1963-9. PubMed ID: 8640969
[TBL] [Abstract][Full Text] [Related]
17. Plasma adrenomedullin relation with Doppler-derived dP/dt in patients with congestive heart failure.
Morales MA; Del Ry S; Startari U; Maltinti M; Prontera C; Emdin M; Giannessi D
Clin Cardiol; 2006 Mar; 29(3):126-30. PubMed ID: 16596836
[TBL] [Abstract][Full Text] [Related]
18. Urinary 8-hydroxy-2'-deoxyguanosine as a novel biomarker for predicting cardiac events and evaluating the effectiveness of carvedilol treatment in patients with chronic systolic heart failure.
Susa T; Kobayashi S; Tanaka T; Murakami W; Akashi S; Kunitsugu I; Okuda S; Doi M; Wada Y; Nao T; Yamada J; Ueyama T; Okamura T; Yano M; Matsuzaki M
Circ J; 2012; 76(1):117-26. PubMed ID: 22008315
[TBL] [Abstract][Full Text] [Related]
19. The effect of beta-blocker (carvedilol) therapy on N-terminal pro-brain natriuretic peptide levels and echocardiographic findings in patients with congestive heart failure.
Gundogdu F; Bozkurt E; Kiziltunc A; Sevimli S; Arslan S; Gurlertop Y; Senocak H; Karakelleoglu S
Echocardiography; 2007 Feb; 24(2):113-7. PubMed ID: 17313541
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators.
Benedict CR; Shelton B; Johnstone DE; Francis G; Greenberg B; Konstam M; Probstfield JL; Yusuf S
Circulation; 1996 Aug; 94(4):690-7. PubMed ID: 8772689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
